Share This Article:

Towards an easier pleurodesis: Ultrasound-guided iodopovidone sclerotherapy in cirrhotic patients with hepatic hydrothorax

Abstract Full-Text HTML Download Download as PDF (Size:166KB) PP. 196-201
DOI: 10.4236/ojgas.2013.33031    3,100 Downloads   4,294 Views   Citations

ABSTRACT

Background and Aim: Hepatic hydrothorax is one of the complications encountered in end stage liver disease. Pleural drainage carries the risk of massive protein and electrolyte depletion as well as the risk of bleeding and hepatic encephalopathy. Pleurodesis following pleural aspiration decreases the chance of pleural effusion recurrence, and has been a widely used long-standing method of controlling recurrent pleural effusions. The aim of this study is to evaluate the effect of pleurodesis using ultrasound-guided iodopovidone sclerotherapy in hepatic hydrothorax. Patients and Methods: This prospective study included 56 patients with clinical, laboratory and radiological evidence of liver cirrhosis and symptomatic right sided hepatic hydrothorax. All patients were subjected to repeated thoracentesis. Ten ml of lidocaine 2% were injected in the pleural space followed by 20 ml of iodopovidone. The follow-up was done after 3 months. Results: The sclerotherapy procedure was successful in 40 out of 56 cases (71.4%), and the success rate was 66.7% in massive effusion and reached 80% in moderate effusion. Twenty eight patients (50%) had to repeat the procedure for a second time, sixteen of which (28.6%) failed despite the second trial and twelve cases (21.4%) showed no fluid reaccumulation. Conclusion: Ultrasound-guided iodopovidone sclerotherapy is an effective approach for a successful pleurodesis in hepatic hydrothorax.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Abdelhafeez, A. , Zakaria, M. , Fathalah, W. and Omran, D. (2013) Towards an easier pleurodesis: Ultrasound-guided iodopovidone sclerotherapy in cirrhotic patients with hepatic hydrothorax. Open Journal of Gastroenterology, 3, 196-201. doi: 10.4236/ojgas.2013.33031.

References

[1] Strauss, R.M. and Boyer, T.D. (1997) Hepatic hydrothorax. Semin Liver Disease, 17, 227-232. doi:10.1055/s-2007-1007200
[2] Albals, W.M., Salem, A.J., Solomon, D.A., et al. (1991) Hepatic hydrothorax: Cause and management. Archives of Internal Medicine, 151, 2383-2388. doi:10.1001/archinte.1991.00400120029005
[3] Kakizaki, S., Katakai, K. and Yoshinaga, T. (1998) Hepatic hydrothorax in the absence of ascites. Liver, 18, 216220. doi:10.1111/j.1600-0676.1998.tb00154.x
[4] Alberts, W.M., Salem, A.J., Solomon, D.A., et al. (1991) Hepatic hydrothorax. Cause and management. Archives of Internal Medicine, 151, 2383-2388. doi:10.1001/archinte.1991.00400120029005
[5] Ackerman, Z. and Reynolds, T.B. (1997) Evaluation of pleural fluid in patients with cirrhosis. Journal of Clinical Gastroenterology, 25, 619-622. doi:10.1097/00004836-199712000-00014
[6] Romero, S., Martín, C., Hernandez, L., et al. (1998) Chylothorax in cirrhosis of the liver—Analysis of its frequency and clinical characteristics. Chest, 114, 154-159. doi:10.1378/chest.114.1.154
[7] Xiol, X., Castellote, J., Cortes-Beut, R., et al. (2001) Usefulness and complications of thoracocentesis in cirrhotic patients. American Journal of Medicine, 111, 67-69. doi:10.1016/S0002-9343(01)00744-6
[8] Milanez de Campos, J.R., Filho, E.A., Webre, E.C., et al. (2000) Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest, 118, 13-17. doi:10.1378/chest.118.1.13
[9] Zaloznik, A.J., Oswald, S.G. and Langin, M. (1983) Intrapleural tetracycline in malignant pleural effusions. Cancer, 51, 752-755. doi:10.1002/1097-0142(19830215)51:4<752::AID-CNCR2820510434>3.0.CO;2-7
[10] Borchardt, J., Smirnov, A., Metchnik, L., et al. (2003) Treating hepatic hydrothorax. British Medical Journal, 326, 751-752. doi:10.1136/bmj.326.7392.751
[11] Liu, L., Haddadin, H.A., Bodian, C.A., et al. (2004) Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest, 126, 142-148. doi:10.1378/chest.126.1.142
[12] Ferrante, D., Arguedas, M.R., Cerfolio, R.J., et al. (2002) Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. American Journal of Gastroenterology, 97, 31723175. doi:10.1111/j.1572-0241.2002.07126.x
[13] Kotran, R., Kumar, V. and Collins, T. (1999) Robbins pathologic basis of disease. 6th Edition, WB Saunders, Philadelphia, 89-134.
[14] Walker-Renard, P.B., Vaughan, L.M. and Sahn, S.A. (1994) Chemical pleurodesis for malignant pleural effusions. Annals of Internal Medicine, 120, 56-64. doi:10.7326/0003-4819-120-1-199401010-00010
[15] Merriam, M.A., Cronan, J.J., Dorfman, G.S., et al. (1988) Radiographically guided percutaneous catheter drainage of pleural fluid collections. American Journal of Roentgenology, 151, 1113-1116. doi:10.2214/ajr.151.6.1113
[16] Cardenas, A., Kelleher, T. and Chopra, S. (2004) Review article: Hepatic hydrothorax. Aliment Pharmacological Therapy, 20, 271-279. doi:10.1111/j.1365-2036.2004.02081.x
[17] Runyon, B.A., Greenblatt, M. and Ring, M.H.C. (1986) Hepatic hydrothorax is a relative contraindication to chest tube insertion. American Journal of Gastroenterology, 81, 566-567.
[18] Ruckdeschel, J.C., Moores, D., Lee, J.Y., et al. (1991) Intrapleural therapy for malignant pleural effusions: A randomized comparison of bleomycin and tetracycline. Chest, 100, 1528-1535. doi:10.1378/chest.100.6.1528
[19] Umit, A., Servet, O., Levent, C., et al. (2009) Bedside talc pleurodesis for malignant pleural effusion: Factors affecting success. Annals of Surgical Oncology, 16, 745750. doi:10.1245/s10434-008-0263-x
[20] Morales-Gomez, J., Tellez-Becerra, J.L., Martinez-Ormeno, J.E., et al. (1993) Pleurodesis with iodopovidone in malignant pleural effusions. Revistadel Instituto Nacionalde Enfermedades Respiratorias Mexico, 6, 71-74.
[21] Kelly-Garcia, J., Roman-Berumen, J.F. and Ibarra-Perez, C. (1997) Iodopovidone and bleomycin pleurodesis for effusions due to malignant epithelial neoplasms. Archives of Medical Research, 28, 583-585.
[22] Barbetakis, N., et al. (2004) Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. BMC Palliative Care, 3, 4. doi:10.1186/1472-684X-3-4
[23] Shaw, P. and Agawal, R. (2004) Pleurodesis for malignnant pleural effusion. (Cochrane Review) The Cochrane Library, 4.
[24] Steven, A.S. (2001) Malignant pleural effusion. Seminars in Respiratory and Critical Care Medicine, 22, 607-615. doi:10.1055/s-2001-18796
[25] Antunes, G., et al. (2003) BTS guidelines for the management of malignant pleural effusions. Thorax, 58, 11291138. doi:10.1136/thorax.58.suppl_2.ii29
[26] Maskell, N.A., Lee, Y.C., Gleeson, F.V., et al. (2004) Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. American Journal of Respiratory and Critical Care Medicine, 170, 377-382. doi:10.1164/rccm.200311-1579OC
[27] Olivares-Torres, C.A., Eaniado-Eaborin, R., Chavez-Garcia, C., et al. (2002) Lodopovidone pleurodesis for recurrent pleural effusions. Chest, 122, 581-583. doi:10.1378/chest.122.2.581
[28] Brant, A. and Eaton, T. (2001) Serious complications with talc slurry pleurodesis. Respirology, 6, 181-185. doi:10.1046/j.1440-1843.2001.00327.x
[29] Gines, P., Arroyo, V., Rodes, J. and Schrier, R. (2005) Ascites and renal dysfunction in liver disease: Pathogenesis diagnosis and treatment. 2nd Edition, Blackwell Publishing Ltd. doi:10.1002/9780470987476

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.